Ultime notizie per Exelixis (NASDAQ:EXEL) Azioni

EXELIXIS INC

Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Exelon Corp

– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% –
– Additional results from dose-finding cohorts will also be presented –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54259233&amp;newsitemid=20250522412302&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=6eda2c7d890705b396b87b517f683533">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo&#xAE;) or a fixed-dose combination of nivolumab and relatlimab (Opdualag&#x2122;) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Biotech

News

General

EXEL

Exelixis To Present STELLAR-002 Trial Data At ASCO 2025 Showing Zanzalintinib Plus Nivolumab Achieved 63% Response Rate And 90% Disease Control In Untreated Advanced Clear Cell RCC, Alongside Additional Dose-Finding Results

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) stock surged 56.32%  after Nvidia disclosed it added a stake in the company via a 13F filing equating to approximately 24.18 million shares. JP Morgan and Needham also raised their respective <a href="https://www.benzinga.com//node/45472274" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock escalated 44.26% after the company announced that it entered into a strategic partnership under a <a href="https://www.benzinga.com//node/45471297" target="_blank" rel="noreferrer noopener">memorandum of understanding</a> with DataVolt.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) stock jumped 33.68% after the company announced a partnership with Webull Pay to power crypto experiences. Additionally, Benchmark raised its price forecast <a href="https://www.benzinga.com//node/45471661" target="_blank" rel="noreferrer noopener">on the stock from $252 to $301</a>.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) shares rose 33.41% after announcing a $12 billion acquisition of LS (Luminus Systems) <a href="https://www.benzinga.com//node/45388224" target="_blank" rel="noreferrer noopener">Power&#8217;s generation assets</a>.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) stock rose 27.19% amid overall market strength following softer-than-expected April inflation readings. Additionally, investors continue to weigh the progress of the U.S.-China trade and President Trump&#8217;s Middle East trip.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares increased 26.86% on reports indicating the House GOP budget will cut but not remove <a href="https://www.benzinga.com//node/45385748" target="_blank" rel="noreferrer noopener">wind and solar tax credits</a>.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock grew 25.52% after the company recently reported better-than-expected financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628. Citigroup raised its <a href="https://www.benzinga.com//node/45418036" target="_blank" rel="noreferrer noopener">price forecast from $45 to $56</a>.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock rose 24.67%. The company announced that NASA had chosen it to launch its Aspera mission and disclosed the return of its Pioneer spacecraft <a href="https://www.benzinga.com//node/45434506" target="_blank" rel="noreferrer noopener">to Varda Space Industries</a>.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) has gained 24.42% in the last week. The stock has rallied since reporting strong first-quarter financial results on May 5. However, the company has a high short float and may be <a href="https://www.benzinga.com//node/45297555" target="_blank" rel="noreferrer noopener">facing a short squeeze</a>.</li>
<li>On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) shares escalated 21.71% after the company reported its first-quarter results, and analysts<a href="https://www.benzinga.com//node/45413809" target="_blank" rel="noreferrer noopener"> revised the price forecast</a>.</li>
<li>Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) stock gained 20.87% after the U.S. and China agreed to reduce most tariffs on each other&#8217;s goods temporarily. A reduction in tariffs could alleviate supply chain and macroeconomic uncertainty and help boost consumer sentiment.</li>
</ol>
Photo via Shutterstock

Equities

Large Cap

Movers

ALAB

COIN

CRWV

FSLR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ONON

RKLB

SMCI

CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$290.00</td>
<td>$37.1K</td>
<td>3.3K</td>
<td>44.8K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/23/25</td>
<td>$65.00</td>
<td>$28.7K</td>
<td>110</td>
<td>2.2K</td>
</tr>
<tr>
<td>PHAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$5.00</td>
<td>$138.9K</td>
<td>13.5K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CLOV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.50</td>
<td>$40.5K</td>
<td>8.0K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$60.00</td>
<td>$38.2K</td>
<td>3.4K</td>
<td>566</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$60.00</td>
<td>$617.0K</td>
<td>1.2K</td>
<td>400</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$500.00</td>
<td>$47.0K</td>
<td>648</td>
<td>205</td>
</tr>
<tr>
<td>EXEL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$47.00</td>
<td>$25.7K</td>
<td>0</td>
<td>43</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$380.00</td>
<td>$28.1K</td>
<td>40</td>
<td>22</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 105 contract(s) at a $290.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $360.0 per contract. There were 3397 open contracts at this strike prior to today, and today 44848 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with bullish sentiment. It expires in 7 day(s) on May 23, 2025. Parties traded 42 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.7K, with a price of $685.0 per contract. There were 110 open contracts at this strike prior to today, and today 2278 contract(s) were bought and sold. 
• Regarding PHAT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>), we observe a call option trade with bearish sentiment. It expires in 91 day(s) on August 15, 2025. Parties traded 1985 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $138.9K, with a price of $70.0 per contract. There were 13569 open contracts at this strike prior to today, and today 2020 contract(s) were bought and sold. 
• Regarding CLOV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>), we observe a call option sweep with bullish sentiment. It expires in 245 day(s) on January 16, 2026. Parties traded 500 contract(s) at a $3.50 strike. This particular call needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $81.0 per contract. There were 8018 open contracts at this strike prior to today, and today 1529 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 35 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $38.2K, with a price of $382.0 per contract. There were 3468 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• Regarding TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we observe a call option trade with bearish sentiment. It expires in 63 day(s) on July 18, 2025. Parties traded 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $617.0K, with a price of $6170.0 per contract. There were 1255 open contracts at this strike prior to today, and today 400 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option sweep with bearish sentiment. It expires in 245 day(s) on January 16, 2026. Parties traded 43 contract(s) at a $500.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $47.0K, with a price of $1095.0 per contract. There were 648 open contracts at this strike prior to today, and today 205 contract(s) were bought and sold. 
• Regarding EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we observe a put option sweep with bearish sentiment. It expires in 189 day(s) on November 21, 2025. Parties traded 43 contract(s) at a $47.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $614.0 per contract. There were 0 open contracts at this strike prior to today, and today 43 contract(s) were bought and sold. 
• Regarding ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we observe a put option sweep with bullish sentiment. It expires in 63 day(s) on July 18, 2025. Parties traded 19 contract(s) at a $380.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $1480.0 per contract. There were 40 open contracts at this strike prior to today, and today 22 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

PHAT

TMDX

9 Health Care Stocks With Whale Alerts In Today's Session

In the current market session, Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock price is at $45.07, after a 2.57% drop. However, over the past month, the company's stock went up by 26.64%, and in the past year, by 114.01%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747411231_0.png" alt="Past Year Chart" />

<h3>A Look at Exelixis P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 53.15 in the Biotechnology industry, Exelixis Inc. has a lower P/E ratio of 21.12. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747411231_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Exelixis

WIIM

Exelixis shares are trading higher after the company recently reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628. On Thursday, Citigroup raised its price target from $45 to $56.

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $42.25, a high estimate of $56.00, and a low estimate of $36.00. This current average has increased by 6.96% from the previous average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747332081_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Exelixis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Exelixis's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 18.16%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 24.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Exelixis: Insights From 8 Analyst Reviews

Citigroup analyst David Lebowitz maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $45 to $56.

Price Target

Citigroup Maintains Buy on Exelixis, Raises Price Target to $56

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) on Tuesday reported its first quarter of 2025 adjusted earnings of 62 cents per share, compared to 17 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by $100 million,&#8221; <a href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance">said</a> Michael M. Morrissey, president and CEO of Exelixis.
The company raised fiscal 2025 sales guidance from $2.15 billion-$2.25 billion to $2.25 billion-$2.35 billion, versus the consensus of $2.25 billion.
Stifel writes, &#8220;We note the NET launch should prove a tailwind to FY25 topline growth and command an additional guidance raise above the $100 million announced today. We continue to believe 2H25 zanzalintinib clinical catalysts will prove a more significant driver of investor enthusiasm&#8230;&#8221;
Analyst Stephen Willey highlights, &#8220;Management noted there is a significant overlap between target NET physicians and legacy Cabometyx prescribers and believes Cabometyx is well positioned to capture a significant portion of the small molecule NET market, which, per management, is estimated at $1B in FY25.&#8221;
Willey maintains the Hold rating for Exelixis and raises the price <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $36 to $38</a>.
Stifel updated fiscal 2025, 2026 and 2027 Cabometyx sales estimates, primarily reflecting continued first-line RCC share gains and an accelerated NET launch trajectory. The analyst updates sales estimates to $2.141 billion, $2.439 billion and $2.712 billion versus $2.062 billion, $2.35 billion, and $2.54 billion, respectively, expected previously.
EXEL Price Action: Exelixis stock was up 20% at $44.3 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Health Care

Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat

U.S. tech stocks extended their weekly rally into Wednesday's session, lifted by renewed investor appetite for risk following a breakthrough in early-week U.S.-China trade negotiations. This reignited hopes for a more <a href="https://www.benzinga.com/topic/tariffs">stable global trade outlook. </a>
The Nasdaq 100 rose 0.5% by midday in New York, reaching levels last seen in late February. Heavyweight chipmakers led the rally, as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged 4% and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) jumped 5%.
Traders welcomed mounting expectations of large-scale investments from Gulf nations into U.S. tech and semiconductor sectors, as President Donald Trump secured new economic agreements with <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Middle Eastern countries</a>, including Saudi Arabia and Syria.
While the Nasdaq marched higher, the S&amp;P 500 stalled and both the Dow Jones Industrial Average and Russell 2000 slipped slightly, indicating a more selective rally focused on high-growth sectors.
Clean energy and solar stocks outperformed again, building on strong Tuesday gains. Investors cheered a less-severe-than-expected revision to clean energy tax credits in the latest Republican tax proposal.
The commodity space told a different story, with gold prices dropping nearly 2%, breaking below the $3,200 per ounce mark for the first time in over a month. 
The yellow metal is now tracking its worst weekly performance since November 2024, with two trading sessions still left this week.
Investors appear to be rotating out of safe-haven assets, as appetite for equities and riskier plays returns on global trade optimism. 
Rising Treasury yields also weighed on broader market sentiment. The yield on the 2-year Treasury note broke above 4%, hitting its highest level in more than two months. Meanwhile, the 30-year bond yield rose 5 basis points to 4.97%, drawing closer to the psychologically important 5% mark—a level often associated with tightening financial conditions and pressure on long-duration assets.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,273.30</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,891.20</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,075.32</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,089.17</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $586.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.3% to $420.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $517.40.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.6% lower to $207.35.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Israeli retail broker Etoro Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) made his debut on the Nasdaq 100 index. Shares were up 26%.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied for a second straight session, jumping 18% to $45.99 on Monday after a 16% gain the previous day.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) advanced 1.9% after securing a major deal with Qatar Airways, which agreed to purchase up to 210 Boeing 787 Dreamliner and 777X aircraft in a transaction valued at $96 billion.</li>
<li>Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) soared 20% after the biotech firm posted first-quarter earnings and revenue that topped Wall Street estimates.</li>
<li>Stocks slated to report earnings after the close include Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) and Steris plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>). </li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45414023/magnificent-seven-add-36-trillion-since-april-lows-is-this-rally-just-beginning">Magnificent Seven Add $3.6 Trillion Since April Lows: Is This Rally Just Beginning?</a></li>
</ul>
Image: Shutterstock

Government

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

CPRT

CSCO

SPDR Dow Jones Industrial Average ETF Trust

ETOR

NVDA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and maintains $40 price target.

Reiteration

RBC Capital Reiterates Outperform on Exelixis, Maintains $40 Price Target

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45390263/exelixis-announces-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
<ul class="wp-block-list">
<li>The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
&#8220;Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in Cabometyx demand, new patient starts, and revenues,&#8221; said Michael M. Morrissey, president and CEO of Exelixis.
&#8220;The&nbsp;Exelixis&nbsp;commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving&nbsp;U.S.&nbsp;regulatory approval in late March. We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025,&#8221; Morrissey added.
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by&nbsp;$100 million,&#8221; Morrissey said.
The company raised fiscal 2025 sales guidance from $2.15 billion—$2.25 billion to $2.25 billion—$2.35 billion, versus the consensus of $2.25 billion.
On Tuesday, Invenra Inc. announced that its collaboration partner, Exelixis, has initiated the dose-escalation stage of the first-in-human Phase 1 study of XB628 in participants with recurrent advanced or <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic solid tumors</a>.
XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45394458/invenra-highlights-exelixis-initiation-of-phase-1-clinical-study-evaluating-xb628-a-first-in-class" rel="noreferrer noopener">death-ligand 1 (PD-L1)</a>.
The molecule was discovered in part through a collaboration between Exelixis and Invenra.
&#8220;Regarding flagship product Cabometyx, we are encouraged by its continued strength in RCC and expect the recent approval in late-line NETs to potentially drive the next leg of growth,&#8221; William Blair analyst Andy T. Hsieh wrote on Wednesday.
&#8220;The NETs market is expected to grow at a 9% compound annual rate to $4.6 billion by 2030. Based on our prior analysis, the total addressable market for Cabometyx in this indication stands at $900 million, thus representing a material expansion opportunity, in our view.&#8221; 
Price Action: At the last check on Wednesday, EXEL stock was up 4.11% at $38.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405716/firstcash-enters-uk-market-with-394-million-acquisition-of-ht-group" target="_blank" rel="noreferrer noopener">FirstCash Enters UK Market With $394 Million Acquisition Of H&amp;T Group</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Morgan Stanley analyst Jefferson Harralson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $40 to $47.

Morgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $47

Exelixis shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628.

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) raises FY2025 sales outlook from $2.15 billion-$2.25 billion to $2.25 billion-$2.35 billion vs $2.25 billion estimate.

Exelixis Raises FY2025 Sales Guidance from $2.15B-$2.25B to $2.25B-$2.35B vs $2.25B Est

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.36 by 72.22 percent. This is a 264.71 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $555.45 million which beat the analyst consensus estimate of $498.18 million by 11.50 percent. This is a 30.62 percent increase over sales of $425.23 million the same period last year.

Earnings Beats

Exelixis Q1 Adj. EPS $0.62 Beats $0.36 Estimate, Sales $555.45M Beat $498.18M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Exelixis will report an earnings per share (EPS) of $0.38.
The announcement from Exelixis is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 0.03% drop in the share price on the following day.
Here's a look at Exelixis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.35</td>
<td>0.30</td>
<td>0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.55</td>
<td>0.47</td>
<td>0.84</td>
<td>0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>13.0%</td>
<td>13.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747072871_0.png" alt="eps graph" />
<h3>Tracking Exelixis's Stock Performance</h3>
Shares of Exelixis were trading at $36.17 as of May 09. Over the last 52-week period, shares are up 77.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Exelixis</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis.
A total of 11 analyst ratings have been received for Exelixis, with the consensus rating being Buy. The average one-year price target stands at $37.82, suggesting a potential 4.56% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Exact Sciences, Moderna and Biomarin Pharmaceutical, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Exact Sciences, with an average 1-year price target of $63.92, suggesting a potential 76.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $42.91, suggesting a potential 18.63% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Biomarin Pharmaceutical, with an average 1-year price target of $94.4, suggesting a potential 160.99% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
In the peer analysis summary, key metrics for Exact Sciences, Moderna and Biomarin Pharmaceutical are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>18.16%</td>
<td>$546.79M</td>
<td>6.19%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>10.86%</td>
<td>$500.55M</td>
<td>-4.22%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-35.93%</td>
<td>$17M</td>
<td>-9.26%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical</td>
<td>Neutral</td>
<td>14.84%</td>
<td>$593.59M</td>
<td>3.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Exelixis ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.
<h3>Get to Know Exelixis Better</h3>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>A Deep Dive into Exelixis's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 18.16%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<a href="https://www.benzinga.com/quote/EXEL/earnings">To track all earnings releases for Exelixis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Exelixis's Earnings Expectations

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 25.73% since its last report. The company recently reported that it has 18.23 million shares sold short, which is 9.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 6.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Exelixis?

19 analysts have expressed a variety of opinions on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.74, a high estimate of $45.00, and a low estimate of $29.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $36.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927228_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Exelixis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Derek Archila &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$25.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;David Lebowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $45.00&#x7C;$38.00 &#x7C; 
&#x7C;Michael Schmidt &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Stephen Willey &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $36.00&#x7C;$30.00 &#x7C; 
&#x7C;Joseph Catanzaro &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $38.00&#x7C;$37.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $34.00&#x7C;$30.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Asthika Goonewardene&#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $43.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Jefferson Harralson &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$30.00 &#x7C; 
&#x7C;Jay Olson &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Perform &#x7C; $33.00&#x7C;$41.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exelixis's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 6.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

Press Releases

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Comments

Exelixis

Notizie

Ultime notizie per Exelixis (NASDAQ:EXEL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO